Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee

Archive ouverte

Masson-Lecomte, Alexandra | Vaillant, Victoire | Roumiguié, Mathieu | Lévy, Stéphan | Pradère, Benjamin | Peyromaure, Michaël | Duquesne, Igor | de la Taille, Alexandre | Lebâcle, Cédric | Panis, Adrien | Traxer, Olivier P. | Leon, Priscilla | Hulin, Maud | Xylinas, Évanguelos | Audenet, François | Seisen, Thomas | Loriot, Yohann | Allory, Yves | Rouprêt, Morgan | Neuzillet, Yann

Edité par CCSD ; MDPI -

International audience. Upper urinary tract urothelial carcinoma (UTUC) is an uncommon disease and its gold-standard treatment is radical nephroureterectomy (RNU). Distal ureterectomy (DU) might be an alternative for tumors of the distal ureter but its indications remain unclear. Here, we aimed to evaluate the oncological outcomes of DU for UTUC of the pelvic ureter. We performed a multicenter retrospective analysis of patients with UTUC who underwent DU. The primary endpoint was 5-year cancer-specific survival (CSS), followed by overall survival (OS), intravesical recurrence-free (IVR) and homolateral urinary tract recurrence-free (HUR) survivals as secondary endpoints. Univariate and multivariate Cox regressions were performed to assess factors associated with outcomes. 155 patients were included, 91% of which were high-risk. 5-year CSS was 84.4%, OS was 71.9%, IVR-free survival was 43.6% and HUR-free survival was 74.4%. Multifocality, high grade and tumor size were the most significant predictors of survival endpoints. Of note, neither hydronephrosis nor pre-operative diagnostic ureteroscopy/JJ stent were associated with any of the endpoints. Perioperative morbidity was minimal. In conclusion, DU stands as a possible alternative to RNU for UTUC of the pelvic ureter. Close monitoring is mandatory due to the high risk of recurrence in the remaining urinary tract.

Suggestions

Du même auteur

A collaborative review of the microsatellite instability/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma

Archive ouverte | Gabriel, Pierre Etienne | CCSD

International audience. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.Objective: To perform a collaborative review of the literature exploring the microsatellite instability...

Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT Study

Archive ouverte | Prost, Doriane | CCSD

International audience

Instauration du traitement adjuvant endovésical par épirubicine des tumeurs de vessie n'infiltrant pas le muscle : premier retour national d'expérience du CC-AFU vessie

Archive ouverte | Rollin, P. | CCSD

International audience. Introduction: Mitomycin C is the gold standard intravesical adjuvant therapy for intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Tensions in the supply of mitomycin have emerged...

Chargement des enrichissements...